However, anti-PD-1/PD-L1 therapy can only be effective in patients with high microsatellite instability-high (MSI-H), high PD-L1 expression, high tumor mutation burden (TMB), and Epstein–Barr virus (EBV)-positive patients. The gene discussed is CD274; the disease is neoplasm.